What is CPIC?
The Clinical Pharmacogenetics Implementation Consortium (CPIC) was formed as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN). CPIC guidelines are peer-reviewed and published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to PharmGKB with supplemental information/data and updates. Anyone with clinical interests in pharmacogenetics is eligible for membership. CPIC’s goal is to address some of the barriers to implementation of pharmacogenetic tests into clinical practice.
One barrier to clinical implementation of pharmacogenetics is the lack of freely available, peer-reviewed, updatable, and detailed gene/drug clinical practice guidelines. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. The guidelines can center on genes (e.g. thiopurine methyltransferase and its implications for thiopurines) or around drugs (e.g. warfarin and CYP2C9 and VKORC1). Priority is given to genotyping tests that are already offered in CLIA-approved clinical settings.
Mary V. Relling, Pharm.D.
Chair, Pharmaceutical Dept.
St. Jude Children's Research Hospital
262 Danny Thomas Place, Room I-5112
Memphis, TN 38105
ph 901 595 2348
fax 901 595 8869
cell 901 428 6903
Teri E. Klein, PhD
Stanford University School of Medicine
443 Via Ortega, Room 213
BioE Altman Lab MC:4245
Stanford, CA 94305
ph 650 736 0156
fax 650 725 3863
Scientific Advisory Board:
Mary V. Relling, Pharm.D. St. Jude Children’s Research Hospital, Memphis
Teri E. Klein, Ph.D. Stanford University
Julie A. Johnson, Pharm.D. University of Florida
Dan M. Roden, M.D. Vanderbilt University
Rachel F. Tyndale, Ph.D. University of Toronto and CAMH
Gwendolyn A. McMillin, Ph.D. ARUP Laboratories
John David Nolan, M.D., Ph.D., Cerner
Robert Nussbaum, M.D. University of California, San Francisco
Heidi Rehm, Ph.D. Partners Healthcare
Marc S. Williams, M.D. Geisinger
Brad Strock, Epic